What is DavosPharma?
DavosPharma is a specialized provider of integrated drug development and regulatory support services. The company offers comprehensive end-to-end solutions, including Chemistry, Manufacturing, and Controls (CMC), toxicology studies, and Investigational New Drug (IND) development. By leveraging a strategic global network, DavosPharma assists biotechnology firms in navigating the intricate landscape of drug development, aiming to accelerate timelines and mitigate risks. Their expertise spans discovery, small molecules, biologics, and drug product formulation, all designed to foster pharmaceutical success. With a legacy of over 50 years, DavosPharma also facilitates connections to a vetted vendor network, optimizing project management and accountability for its clients.
How much funding has DavosPharma raised?
DavosPharma has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in DavosPharma
PPP
Public-Private Partnership
What's next for DavosPharma?
The recent major strategic investment signals a pivotal phase for DavosPharma, likely enabling expansion of its service offerings, enhancement of its technological infrastructure, and further penetration into key global markets. This capital infusion is expected to bolster its capacity to support a broader range of biotech clients, from early-stage discovery through to late-stage regulatory submissions. The company's focus on streamlining drug development processes and reducing associated risks positions it favorably to capitalize on the increasing demand for specialized pharmaceutical support services.
See full DavosPharma company page
